EVE.SW
Price:
$0.818
Market Cap:
$5.90M
EvoNext Holdings SA engages in the business of researching, developing, and commercializing novel nutritional, healthcare, and wellness ingredients. The company was founded by Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith in 2004 and is headquartered in Reinach, Switzerland.
Industry
Biotechnology
IPO Date
2005-05-03
Stock Exchange
SIX
Ticker
EVE.SW
According to EvoNext Holdings S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -6.82. This represents a change of 262.92% compared to the average of -1.88 of the last 4 quarters.
The mean historical PE Ratio of EvoNext Holdings S.A. over the last ten years is -4.24. The current -6.82 PE Ratio has changed 15.98% with respect to the historical average. Over the past ten years (40 quarters), EVE.SW's PE Ratio was at its highest in in the June 2024 quarter at 1.29. The PE Ratio was at its lowest in in the June 2007 quarter at -1518.04.
Average
-4.24
Median
-4.58
Minimum
-12.73
Maximum
6.22
Discovering the peaks and valleys of EvoNext Holdings S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 55.10%
Maximum Annual PE Ratio = 6.22
Minimum Annual Increase = -16939.48%
Minimum Annual PE Ratio = -12.73
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 6.22 | -16939.48% |
| 2023 | -0.04 | -98.18% |
| 2022 | -2.02 | -29.18% |
| 2021 | -2.86 | -46.29% |
| 2020 | -5.32 | -31.77% |
| 2019 | -7.80 | 31.15% |
| 2018 | -5.95 | 55.10% |
| 2017 | -3.83 | -52.60% |
| 2016 | -8.09 | -36.47% |
| 2015 | -12.73 | -25.12% |
The current PE Ratio of EvoNext Holdings S.A. (EVE.SW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.39
5-year avg
-0.80
10-year avg
-4.24
EvoNext Holdings S.A.’s PE Ratio is less than Addex Therapeutics Ltd (-1.03), less than Basilea Pharmaceutica AG (10.31), less than Molecular Partners AG (-1.95), less than Newron Pharmaceuticals S.p.A. (16.94), less than Santhera Pharmaceuticals Holding AG (-2.38),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.03 | $8.45M | |
| 10.31 | $655.21M | |
| -1.95 | $126.22M | |
| 16.94 | $401.21M | |
| -2.38 | $158.10M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like EvoNext Holdings S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like EvoNext Holdings S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is EvoNext Holdings S.A.'s PE Ratio?
How is the PE Ratio calculated for EvoNext Holdings S.A. (EVE.SW)?
What is the highest PE Ratio for EvoNext Holdings S.A. (EVE.SW)?
What is the 3-year average PE Ratio for EvoNext Holdings S.A. (EVE.SW)?
What is the 5-year average PE Ratio for EvoNext Holdings S.A. (EVE.SW)?
How does the current PE Ratio for EvoNext Holdings S.A. (EVE.SW) compare to its historical average?